Posts for Ticker ‘FMS’

Top Pre-Market Analyst Upgrades (BBY, CB, DVA, DFT, FCX, FMS, MWE, MCHP, WFT)

Money_stack_picThese are some of the top per-market analyst upgrades and positive calls we are seeing from Wall Street this Thursday morning:

  • Best Buy (BBY) Raised to Overweight at Barclays.
  • Chubb (CB) Raised to Buy at Bank of America-Merrill Lynch.
  • DaVita (DVA) Started as Outperform at RBC.
  • Dupont Fabros Tech (DFT) Raised to Buy at UBS.
  • Freeport McMorRan (FCX) Raised to Hold at Canccord.
  • Fresenius Medical (FMS) Started as Outperform at RBC.
  • MarkWest Energy (MWE) Raised to Outperform at Morgan Keegan.
  • Microchip Tech (MCHP) Raised to Overweight at Barclays.
  • Weatherford (WFT) Raised to Overweight at JPMorgan.

Jon C. Ogg
January 29, 2009

Microcap Featured in Dialysis Investing (XCR, NXTM, DVA, FMS, DCAI)

Xcorporeal, Inc. (AMEX: XCR) is a potential undiscovered gem in microcap and low-priced stock investing, and it is in the arena of kidney dialysis.  This week’s "INSIDE WALL STREET" segment in Business Week featured this stock, and this may be their most unusual pick in months with perhaps the greatest upside potential if it can live up to the hopes and plans.

This one has been under review for our "10 Stocks Under $10" weekly letter, although we have not yet added it to the list because of its performance and lack of history.  Xcorporeal first came to us after it’s Wearable Artificial Kidney (WAK) prototype device was featured in the December 15, 2007 journal issue of The Lancet, an influential medical journal.

It is entering a space dominated by public companies such as DaVita Inc. (NYSE: DVA), Dialysis Corp. of America (NASDAQ: DCAI), Fresenius Medical Care AG & Co. KGaA (NYSE: FMS), and Nxstage Medical, Inc. (NASDAQ: NXTM). Of the public dialysis companies, this is also the most risky stock of the ones we have reviewed in the dialysis companies.

Read More »